RMS™ MEDICAL PRODUCTS

FREEDOM60® Syringe Infusion System

FreedomEdge® Syringe Infusion System

HIgH•Flo™ Subcutaneous Safety Needle Sets

HIgH•Flo Super26™ Subcutaneous Safety Needle Sets

precision FLOW RATE TUBING™

Q1 2019 CONFERENCE CALL

May 1, 2019

OTCQX: REPR

Improving the Patient Experience

DISCLAIMER

This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "plan," "goal," "seek," “vision, “confident,” "future," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our Strategic Plan and other goals. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM Syringe Infusion System; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; the costs, duration and ultimate outcome of litigation; and general economic and business conditions. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Non-GAAP Adjusted EBITDA

Adjusted EBITDA excludes from net loss: tax (benefit)/expense, depreciation and amortization, interest income, operating expenses associated with the Company's organizational changes, litigation costs, and stock compensation expense.

Non-GAAP Measures

This presentation includes non-GAAP financial measures that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. A reconciliation of our non-GAAP measures is included in this presentation.

Don Pettigrew
President & CEO

Karen Fisher, CPA
Chief Financial Officer

FIRST-EVER $5 MILLION NET SALES QUARTER ($ in MMs)

Q1 2019 v. Q1 2018

- 23.3% rise in net sales – a quarterly record
- Gross margin of 61.3%
- Net loss of $85,000
- 10.4% increase in Adjusted EBITDA



- Adjusted EBITDA excludes from net loss: tax (benefit)/expense, depreciation and amortization, interest income, operating expenses associated with the Company's organizational changes, litigation costs, and stock compensation expense. For a reconciliation of non-GAAP Adjusted EBITDA to GAAP net income, see slide 14 of this presentation.

HIgH-Flo Super26™
Subcutaneous Safety Needle Sets

- HIgh-FLO Super26™ Subcutaneous Needle Sets
- Indicated for subcutaneous immunoglobulin / medication infusion in the home, hospital, or ambulatory settings
- Reflects commitment to product innovation

STRENGHTENED MANAGEMENT TEAM AND BOARD

Brian Schiller, Ph.D.
VP Medical Affairs

- Joined RMS Medical February 2019
- Senior Director, Head of Field Medical, NA Medical Affairs at Sanofi (Genzyme)
- Associate Director of Medical Affairs and Associate Director of Clinical Research and Medical Affairs at Avanir Pharmaceuticals, leadership roles at Amgen and Bristol Myers Squibb
- M.S. Kinesiology/Physiology, Ph.D. Applied Physiology from the University of Colorado-Boulder

Kathy S. Frommer
Independent Director

- Elected to the Board of Directors on April 23, 2019
- 30 years of IT industry experience
- Co-founder & CEO (1989 -2005) of CRS Retail Systems, one the largest providers of software to specialty stores in the US; sold to Epicor Software in 2005
- CRS products helped drive sales, improve customer service and reduce operating costs
- Board member, SUNY Orange County Foundation and Bethel Woods Center for the Arts

IN MEMORIUM: ARTHUR J. RADIN

Arthur was a leader and a friend who provided wise counsel, a steady hand, and genuine warmth as a member of our board. His business acumen and financial expertise helped shape a variety of issues that have been critical to the transformation of our company. The entire RMS Medical family mourns his loss.

OUR CURRENT OPPORTUNITY: PIDD AND CIDP

We are operating in two of the largest market segments approved for Ig therapy

$185 - $260 Million

U.S. Addressable PIDD Market (2,3)

U.S. Patient Population ~270,000 (1)

$25 - $36 Million

U.S. Addressable CIDP Market (2,3)

U.S. Patient Population ~ 25,000 (2)

Primary Immunodeficiency Disease (PIDD)

A group of more than 350 chronic disorders in which part of the body's immune system is missing or functions improperly.

270,000 U.S. patient population. (1)

70,000 patients are receiving Ig therapy today.(2)

20,000 patients are receiving SCIg with the RMS FREEDOM system. (3)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms, orthostatic dizziness, tingling and numbness of hands and feet.

2018: Hizentra® becomes first and only SCIg for treatment of CIDP.

(1) Immune Deficiency Foundation; (2) Industry research; (3) RMS estimates

SUBSTANTIAL ADDRESSABLE MARKET

Sources: Transparency Market Research US CDC, NIH, Grand View Research, MSD Healthcare Solutions, Immune Deficiency Foundation, Management Estimates
Internal estimates

Total Available Market (TAM)

Global Home Infusion Market
+9% CAGR to $26.7B by 2020

Serviceable Available Market (SAM)

$7.4B North America Home Infusion Therapy Market, Growing at 8% Per Annum

$1.3B North America Market for SCIg, +14% SCIg CAGR 2016-2024

OUS estimated to be >2X North America

RMS Target Market

$500 M U.S. Home Infusion Equipment Market

RMS Net Sales

FY 2018: $17.4 M Net Sales, +12.4% YOY

Q1 2019: $5.0 M Net Sales, +23.3% YOY

- **Newly diagnosed PIDD patients expected to be prescribed Ig therapy with subcutaneous delivery**
  270,000 patients today [2]
- **PIDD transitioning from IVIg therapy to subcutaneous Ig therapy**
  70,000 patients today [1]
- **Expanded indications for immunoglobulins delivered with the Freedom system**
  CIDP: 25,000 patients in US [1]
- **Pharmaceutical companies developing subcutaneous administration indications for large molecules and biosimilars using the Freedom system**
  1.0 M patients [1]

(1) Industry research, RMS estimate; (2) Immune Deficiency Foundation

RMS Medical's Freedom60® is featured at www.hizentra.com and in a national advertising campaign for Hizentra® SCIg therapy

FREEDOM60®
Syringe Infusion System

Source: www.hizentra.com

THE MOVE AWAY FROM HOSPITAL CARE

- Targeting post-acute care settings that comprise ~60% of the total U.S. infusion market: home care, SNF and physician outpatient
- Reduced episodic and annual total cost of care
  - Employers are demanding health insurers reign in rising costs
  - Patients are realizing they pay more out-of-pocket at higher cost settings
  - Per-day savings for home infusion can be up to 90% versus institutional setting
- Safety
  - Reduces incidence of hospital acquired infections (HAI), especially important for the immunocompromised
  - ~ 1 in 25 patients experiences an HAI; +1.0 M occur annually
- Patient preference
  - 86% patients prefer being treated at home
- Reduces avoidable hospital readmission rates



Source: www.beckershospitalreview.com/patient-engagement/why-hospital-partnerships-with-home-infusion-providers-helps-consumers.html

Q1 2019 FINANCIAL SUMMARY

	Three Months Ended 3/31/19	Three Months Ended 3/31/18
Net Sales	**$ 5.0 M**	$ 4.0 M
Gross Profit	**$ 3.0 M**	$ 2.5 M
Gross Margin	**61.3%**	61.1%
Total Operating Expenses	**$ 3.2 M**	$ 2.0 M
Net (Loss) Income	**$(0.1) M**	$ 0.4 M
Non-GAAP Adjusted EBITDA	**$ 0.9 M**	$ 0.8 M

NON-GAAP RECONCILIATION

RECONCILIATION OF GAAP NET (LOSS)/INCOME TO NON-GAAP ADJUSTED EBITDA:		Three Months Ended March 31,		
		2019		2018
GAAP Net (Loss)/Income	$	(85,390)	$	403,427
Tax (Benefit)/Expense		(22,099)		107,741
Depreciation/Amortization		83,651		74,578
Interest Income, Net		(17,480)		(615)
Reorganization Charges		354,926		72,551
Litigation		492,515		155,800
Stock Compensation Expense		121,875		27,183
Non-GAAP Adjusted EBITDA	$	927,998	$	840,665

No Debt, Simple Cap Structure

BALANCE SHEET	March 31, 2019	December 31, 2018
Cash & Cash Equivalents	$ 2.6 M	$ 3.8 M
Certificates of Deposit	$ 1.5 M	$ 1.5 M
Current Assets	$ 9.6 M	$ 9.0 M
Total Assets	$ 11.6 M	$ 10.5 M
Total Liabilities	$ 2.4 M	$ 1.6 M
Shareholders' Equity	$ 9.2 M	$ 9.0 M

SHARES OUTSTANDING	March 31, 2019
Basic Shares Outstanding	38.2 M
Options Outstanding (WAEP $1.17)	3.5 M
Warrants (WAEP $0.45) (exp. August 2019)	1.0 M
Fully Diluted Shares	42.7 M

STRATEGIC PLAN

TO BECOME THE PREFERRED DRUG DELIVERY PARTNER FOR SPECIFIC INFUSION THERAPIES IN SELECT MARKETS

FINANCIAL GOALS

- **$50M Net Revenue Run Rate** by end of 2022
- **Gross Margin of 70%+** by end of 2022
- **20%+ Annual Organic Revenue Growth** for each year

Phase 1

Grow & Harvest

2019 - 2020

- Maintain baseline business
- Penetration of PIDD and CIDP
  - ***Pharma reps***
  - ***Home infusion sales reps***
  - ***Distributors***
- New product development/ launch
- New indications
- Government partnership
- OUS development
- Pharma collaboration
- Funnel of clinical trials
- Margin improvement

Phase 2

Expand & Innovate

2020 - 2021

- Continued execution of Phase 1
- New products
- Expanded indications
- Post-acute care
- European expansion

Phase 3

Accelerated Growth

2021 - Beyond

- Continued Phase 1 & 2 execution
- New drugs and indications
- Post-acute care growth
- Global expansion
- Market share gains

PERFORMANCE AGAINST OUR OBJECTIVES

FINANCIAL GOALS

$50M Net Revenue Run Rate by end of 2022	Gross Margin of 70%+ by end of 2022	20%+ Annual Organic Revenue Growth for each year

Phase 1

Grow & Harvest

2019 - 2020

- Maintain baseline business
- Penetration of PIDD and CIDP
  - ***Pharma reps***
  - ***Home infusion sales reps***
  - ***Distributors***
- New product development/ launch
- New indications
- Government partnership
- OUS development
- Pharma collaboration
- Funnel of clinical trials
- Margin improvement

- Strengthened relationships with current customer base
- FDA 510(k) clearance for HIgh-FLO Super26™ Subcutaneous Needle Sets
- Enhanced management team and board
- Initiatives underway designed to reduce COGS to achieve 70%+ gross margin goal
- Continuing to build on 2018 FDA clearance of Hizentra® for indication to treat CIDP

CONCLUDING REMARKS

Mission Statement

To improve the quality of life of patients around the world through the development and delivery of high quality, innovative and easy-to-use therapeutic solutions

- Well-respected family of products
- Addressable markets experiencing double-digit growth
- Significant market share with multiple expansion catalysts
- Clean balance sheet, liquidity and simple cap structure
- Refreshed and focused management team
- Razor – razorblade model drives recurring revenue

RMS™ MEDICAL PRODUCTS

FREEDOM60® Syringe Infusion System

FreedomEdge® Syringe Infusion System

HIgH•Flo™ Subcutaneous Safety Needle Sets

HIgH•Flo Super26™ Subcutaneous Safety Needle Sets

precision FLOW RATE TUBING™

Q1 2019 CONFERENCE CALL

May 1, 2019

OTCQX: REPR

Improving the Patient Experience